Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)

被引：2
|
作者：
Sasaki, Koji [1 ]
Kantarjian, Hagop M. [1 ]
Samra, Bachar [1 ]
Short, Nicholas J. [2 ]
Khoury, Joseph D. [3 ]
Kanagal-Shamanna, Rashmi [3 ]
Konopleva, Marina Y. [1 ]
Jain, Nitin [1 ]
DiNardo, Courtney D. [1 ]
Khouri, Rita [1 ]
Garcia-Manero, Guillermo [1 ]
Kadia, Tapan M. [1 ]
Wierda, William G. [1 ]
Tippett, Nicole [1 ]
Garris, Rebecca [1 ]
Jeanis, Victoria [1 ]
Daver, Naval G. [1 ]
Thompson, Philip A. [1 ]
Yilmaz, Musa [1 ]
Cortes, Jorge E. [1 ]
O'Brien, Susan M. [4 ]
Ravandi, Farhad [1 ]
Jabbour, Elias [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[4] Univ Calif Irvine Hlth, Div Hematol Oncol, Dept Med, Chao Family Comprehens Canc Ctr, Orange, CA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-128619
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Wang, Jing
    Jiang, Qian
    Xu, Lan-ping
    Zhang, Xiao-hui
    Chen, Huan
    Qin, Ya-zhen
    Ruan, Guo-rui
    Jiang, Hao
    Jia, Jin-song
    Zhao, Ting
    Liu, Kai-Yan
    Jiang, Bin
    Huang, Xiao-Jun
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (04) : 741 - 750
  • [32] Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience.
    Papayannidis, Cristina
    Iacobucci, Ilaria
    Soverini, Simona
    Colarossi, Sabrina
    Gnani, Alessandra
    Lonetti, Annalisa
    Baldazzi, Carmen
    Testoni, Nicoletta
    Amabile, Marilina
    Ottaviani, Emanuela
    Abbenante, Maria Chiara
    Curti, Antonio
    Paolini, Stefania
    Lama, Barbara
    Castagnetti, Fausto
    Poerio, Angela
    Clissa, Cristina
    Parisi, Sarah
    Polverelli, Nicola
    Guadagnuolo, Viviana
    Piccaluga, Pier Paolo
    Rosti, Gianantonio
    Baccarani, Michele
    Martinelli, Giovanni
    BLOOD, 2009, 114 (22) : 800 - 800
  • [33] Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case-control study
    Cai, Jiaoyang
    Liu, Hu
    Chen, Yumei
    Yu, Jie
    Gao, Ju
    Jiang, Hua
    Zhai, Xiaowen
    Ju, Xiuli
    Wu, Xuedong
    Wang, Ningling
    Tian, Xin
    Liang, Changda
    Fang, Yongjun
    Zhou, Fen
    Li, Hong
    Sun, Lirong
    Yang, Liangchun
    Guo, Jing
    Liu, Aiguo
    Li, Chi-kong
    Zhu, Yiping
    Tang, Jingyan
    Yang, Jun J.
    Shen, Shuhong
    Cheng, Cheng
    Pui, Ching-Hon
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2023, 38
  • [34] HEMATOPOIETIC STEM CELL TRANSPLANT VERSUS CHEMOTHERAPY PLUS TYROSINE KINASE INHIBITOR IN THE TREATMENT OF PEDIATRIC PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Salami, K.
    Alkayed, K.
    Halalsheh, H.
    Ahmed, A.
    Riziq, M.
    Madanat, F.
    PEDIATRIC BLOOD & CANCER, 2013, 60 : 64 - 64
  • [35] Therapy Optimization and Challenges in MRD-positive or recurrent Philadelphia Chromosome-positive acute Lymphocytic Leukemia (Ph plus ALL)
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (11) : 614 - 615
  • [36] CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months
    Yao, Zhenzhen
    Gu, Bin
    Chen, Jia
    Xu, Yang
    Chen, Feng
    Xue, Shengli
    Qiu, Huiying
    Tang, Xiaowen
    Han, Yue
    Chen, Suning
    Sun, Aining
    Yu, Lei
    Zhang, Yanming
    Wu, Depei
    Wang, Ying
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [37] CD19 chimeric antigen receptor T-cell therapy in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia without complete molecular response at 3 months
    Zhenzhen Yao
    Bin Gu
    Jia Chen
    Yang Xu
    Feng Chen
    Shengli Xue
    Huiying Qiu
    Xiaowen Tang
    Yue Han
    Suning Chen
    Aining Sun
    Lei Yu
    Yanming Zhang
    Depei Wu
    Ying Wang
    Blood Cancer Journal, 13
  • [38] Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib
    Wassmann, B
    Pfeifer, H
    Scheuring, UJ
    Binckebanck, A
    Gökbuget, N
    Atta, J
    Brück, P
    Rieder, H
    Schoch, C
    Leimer, L
    Schwerdtfeger, R
    Ehninger, G
    Lipp, T
    Perz, J
    Stelljes, M
    Gschaidmeier, H
    Hoelzer, D
    Ottmann, OG
    BLOOD, 2004, 103 (04) : 1495 - 1498
  • [39] Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) plus ponatinib vs. HCVAD plus dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).
    Sasaki, Koji
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Thomas, Deborah A.
    Daver, Naval Guastad
    Kadia, Tapan M.
    Konopleva, Marina
    Jain, Nitin
    Short, Nicholas James
    Issa, Ghayas C.
    Jeanis, Vicky
    Moore, H. Gal
    Garris, Rebecca S.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    O'Brien, Susan Mary
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL)
    Ottmann, Oliver G.
    Wassmann, Barbara
    Pfeifer, Heike
    Giagounidis, Aristoteles
    Stelljes, Matthias
    Duehrsen, Ulrich
    Schmalzing, Marc
    Wunderle, Lydia
    Binckebanck, Anja
    Hoelzer, Dieter
    CANCER, 2007, 109 (10) : 2068 - 2076
12345